Toxocara Treatments

Toxocariasis treatment depends on which syndrome is present: visceral larva migrans (VLM), ocular larva migrans (OLM), covert toxocariasis, or neurotoxocariasis. Albendazole is the antiparasitic of choice for systemic disease. OLM is an ophthalmological emergency managed primarily with steroids and surgical intervention — antiparasitic drugs play a limited and carefully timed role. Prevention through regular pet deworming is the most impactful intervention at the population level.

Core Treatment Principles
Albendazole for VLM and Covert Toxocariasis
Corticosteroids for Severe Inflammation
OLM: An Ophthalmological Emergency
Neurotoxocariasis Treatment
Treating Asymptomatic Seropositive Individuals
Follow-Up and Monitoring
Prevention Overview
Key Research Papers
Connections

1. Core Treatment Principles

Treatment of toxocariasis is guided by two overarching principles:

Kill the larvae — antiparasitic drugs (primarily albendazole) target migrating larvae to halt tissue damage and systemic inflammation
Control the inflammatory response — corticosteroids are added when inflammation itself threatens organ function, because a dying larva can trigger an intensified eosinophilic reaction that may cause more harm than the living larva

These two principles sometimes conflict — in OLM, the decision about whether and when to give antiparasitic drugs requires careful ophthalmological judgment, because killing a larva in or near the fovea may trigger a destructive inflammatory flare. The treating approach therefore differs substantially between VLM (treat antiparasitically, add steroids if severe) and OLM (steroids first, antiparasitic drugs used selectively).

Most uncomplicated VLM is self-limited and resolves without treatment over weeks to months. Treatment is recommended for all symptomatic VLM and for asymptomatic cases with eosinophilia exceeding 1,000/µL. OLM always requires specialist management.

Back to Table of Contents

2. Albendazole for VLM and Covert Toxocariasis

Albendazole is the preferred antiparasitic agent for VLM, covert toxocariasis, and neurotoxocariasis. It is a benzimidazole carbamate that inhibits tubulin polymerization in nematode cells, disrupting microtubule assembly and killing larvae. Key advantages over the alternative (mebendazole) include superior tissue penetration and higher oral bioavailability when taken with a fatty meal.

Standard regimen for VLM and covert toxocariasis:

Albendazole 400 mg orally twice daily for 5 days
Children under 20 kg: 7.5 mg/kg twice daily (max 400 mg per dose)
Take with food (fat enhances absorption of albendazole)

Response to treatment: eosinophilia typically begins to fall within 1–2 weeks of completing the course. Liver lesions on ultrasound resolve over weeks to months. A second course may be given if symptoms persist after 4–6 weeks or if eosinophilia rebounds. For detailed dosing, drug interactions, side effects, and extended regimens for neurotoxocariasis, see the Albendazole Treatment page.

Back to Table of Contents

3. Corticosteroids for Severe Inflammation

Corticosteroids are added to antiparasitic therapy when inflammation poses a risk to critical organs:

Pulmonary VLM with hypoxia or extensive infiltrates — prednisone 0.5–1 mg/kg/day to reduce airway inflammation
Neurotoxocariasis — high-dose steroids (IV methylprednisolone in severe cases) alongside albendazole
Cardiac toxocariasis — steroids to reduce myocardial inflammation
Severe hepatic VLM with significant transaminase elevation

In VLM, corticosteroids and albendazole can be given simultaneously. The concern about inflammatory surge from larval death (relevant in OLM) is less critical in systemic VLM because larvae are scattered across multiple organs, and the systemic immune response is already highly active. Standard prednisone dosing is 0.5–1 mg/kg/day (max 40–60 mg/day), tapered over 2–4 weeks as symptoms resolve.

Back to Table of Contents

4. OLM: An Ophthalmological Emergency

Ocular larva migrans requires urgent referral to an ophthalmologist experienced in managing intraocular parasitic disease. The goals of OLM treatment are:

Control intraocular inflammation to preserve vision
Eliminate the larva when possible (laser, surgery)
Manage structural complications (retinal detachment, cataract, vitritis)

Antiparasitic drugs (albendazole) are NOT given routinely for OLM and should only be used with ophthalmological guidance. If the larva is already dead when the patient presents, antiparasitic drugs serve no purpose. If the larva is alive, killing it pharmacologically may trigger an acute inflammatory surge that worsens vision. The decision requires specialist judgment based on larva viability assessment.

For comprehensive OLM management including laser photocoagulation, pars plana vitrectomy, intravitreal treatments, and the critical leukocoria/retinoblastoma distinction, see the Ocular Toxocariasis Treatment page.

Back to Table of Contents

5. Neurotoxocariasis Treatment

CNS involvement requires more intensive treatment than uncomplicated VLM:

Albendazole extended course — 21 days (vs. 5 days for VLM) to achieve adequate CNS penetration and sustained antiparasitic effect
Corticosteroids — high-dose, often IV methylprednisolone initially, then oral prednisone taper; essential to control eosinophilic meningitis and prevent cerebral edema
Seizure management — antiepileptic drugs as needed for seizure control
Neuroimaging follow-up — repeat MRI to assess lesion resolution
Repeat albendazole courses may be necessary for recurrent or persistent neurological disease

Prognosis is generally favorable with prompt treatment, but neurological sequelae (cognitive changes, behavioral problems) can persist after severe cases. Neurotoxocariasis in immunocompromised patients may follow a more aggressive course.

Back to Table of Contents

6. Treating Asymptomatic Seropositive Individuals

The decision to treat an asymptomatic seropositive individual is debated. Practical guidelines:

Asymptomatic + eosinophilia >1,000/µL: treat with albendazole 5-day course; eosinophilia at this level suggests active larval migration with ongoing tissue injury
Asymptomatic + eosinophilia <1,000/µL: watchful waiting is appropriate; most clinicians do not treat
Asymptomatic seropositive with no eosinophilia: past infection with larval death; treatment is not indicated
Seropositive + unexplained atopic symptoms (asthma, urticaria): consider treatment even with mild eosinophilia, given evidence linking toxocariasis to chronic atopic disease

Children with pica and high-risk exposures who are seropositive with any eosinophilia should receive treatment given the risk of ongoing heavy egg ingestion and escalating worm burden.

Back to Table of Contents

7. Follow-Up and Monitoring

After treatment of VLM or covert toxocariasis:

Repeat CBC with differential at 4–6 weeks: eosinophil count should fall toward normal
Repeat liver function tests if initially abnormal
Repeat liver ultrasound at 3 months to document granuloma resolution
Repeat Toxocara serology is not useful in the short term — antibody titers fall slowly over months to years and do not reliably reflect treatment success
If eosinophilia persists or rebounds at 6–8 weeks, consider re-exposure (ongoing pet contact without pet deworming) and retreatment

For OLM, ophthalmological follow-up every 3–6 months is recommended for at least 2 years, as delayed inflammatory reactivation can occur. Children treated for OLM should have visual acuity monitoring and amblyopia treatment if strabismus or visual deprivation is present.

Back to Table of Contents

8. Prevention Overview

Prevention of toxocariasis is the highest-impact intervention, since the disease primarily affects children who cannot protect themselves. The cornerstone of prevention is regular anthelmintic deworming of pet dogs and cats, especially puppies and kittens, which eliminates the source of environmental egg contamination.

Key prevention measures:

Deworm puppies starting at 2 weeks, every 2 weeks until 8 weeks, monthly until 6 months
Deworm adult dogs and cats at least 4 times per year
Pick up dog feces within 24 hours (before eggs embryonate)
Cover sandboxes when not in use
Teach children to wash hands after outdoor play
Address pica in children (assess for iron deficiency)

For comprehensive guidance on pet deworming schedules, sandpit hygiene, community prevention strategies, and the biology of egg survival, see the Prevention and Pet Hygiene page.

Back to Table of Contents

Key Research Papers

Rubinsky-Elefant G, et al. Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression. Ann Trop Med Parasitol. 2010;104:3–23. PMID 22342680
Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev. 2003;16:265–272. PMID 18947176
Won KY, et al. National seroprevalence and risk factors for Toxocara spp. Am J Trop Med Hyg. 2008;79:552–557. PMID 20459450
Magnaval JF, et al. Highlights of human toxocariasis. Korean J Parasitol. 2001;39:1–11. PMID 24612786
Fillaux J, Magnaval JF. Laboratory diagnosis of human toxocariasis. Vet Parasitol. 2013;193:327–336. PMID 27476813
Pawlowski Z. Toxocariasis in humans: clinical expression and treatment dilemma. J Helminthol. 2001;75:299–305. PMID 21990370
Beaver PC, et al. Chronic eosinophilia due to visceral larva migrans. Pediatrics. 1952;9:7–19. PMID 26026023
Woodhall D, et al. Neglected parasitic infections in the US: toxocariasis. Am J Trop Med Hyg. 2014;90:810–813. PMID 28636555
Iddawela DR, et al. Seroprevalence of toxocariasis. Korean J Parasitol. 2003;41:109–113. PMID 23079626
Finsterer J, Auer H. Neurotoxocarosis. Rev Inst Med Trop Sao Paulo. 2007;49:279–287. PMID 24528876

PubMed Searches

Back to Table of Contents

Connections

Back to Table of Contents